跳至主要内容
临床试验/CTRI/2024/01/061600
CTRI/2024/01/061600尚未招募Unknown

Study of Inj. Sepsivac® in gram negative sepsis

Cadila Pharmaceuticals LTD1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2024年1月24日最近更新:

试验速览

阶段
Unknown
状态
尚未招募
入组人数
25
试验地点
1
主要终点
28 days all-cause mortality

研究概览

简要总结

Based on the efficacy and safety data of Mycobacterium w (Mw) as observed in previous clinical studies, we hypothesize that using Mw as adjuvant to standard treatment in sepsis via intravenous route will be safe as well as effective in decreasing complications, hasten the organ function recovery and reduce the 28 day mortality associated with sepsis.

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • Presumed or Suspected or Confirmed Sepsis due to gram negative infection.

排除标准

  • • History of allergic reactions attributed to Inj.
  • Sepsivac® or any of its excipients • Pregnant and lactating women.

结局指标

主要结局

28 days all-cause mortality

时间窗: Day 1, 2, 3, 4, 7, 14, 28

次要结局

  • 1. Change in clinical and laboratory parameters(2. Change in SOFA score)

研究者

申办方类型
Pharmaceutical industry-Indian
责任方
Principal Investigator
主要研究者

Dr Madhusudhan Jaju

Yashoda Hospital

研究点 (1)

Loading locations...

相似试验